Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases. An open Horizon Europe Framework Program for consortia.
Single stage with dead-line 15 march 2023 ExpectedOutcome: Research and innovation (R&I) actions to be supported under this topic must work towards results that contribute to all the following expected outcomes. Scope: There are over 7 000 rare diseases resulting in 30 million patients1 in Europe with a rare disease. Globally more than 300 million patients2 are